Allogeneic stem cell transplantation from HLA-matched siblings (MSD-SCT) for elderly patients with severe aplastic anemia (SAA) is not a widely accepted first-line treatment. Recently, fludarabine, lower-dose cyclophosphamide and antithymocyte globulin conditioning (Flu/lower-dose Cy/ATG) with lower toxicities has been investigated. To determine whether this regimen can overcome the negative effects of age, we analyzed 117 adult patients with SAA who received MSD-SCT using Flu/lower-dose Cy/ATG, and compared outcomes between 63 younger age group (YAG; ⩽ 40 years) and 54 older age group (OAG; 440 years) patients. No primary graft failure was observed. Neutrophil engraftment was significantly faster in the YAG compared with the OAG (12 vs 13 days; P = 0.04). The incidences of acute grade II-IV (9.5% vs 9.3% at day 100; P = 0.42) and chronic GVHD (8.1% vs 9.5% at 5 years; P = 0.80), secondary graft failure (20.8% vs 7.9% at 5 years; P = 0.11) and transplant-related mortality (5.4% and 11.1% at 5 years; P = 0.91) were not significantly different between the YAG and OAG. In addition, failure-free (73.7% vs 81.0% at 5 years; P = 0.73) and overall survival rates (93.7% vs 88.9% at 5 years; P = 0.20) were comparable. Our results suggest that MSD-SCT using Flu/lower-dose Cy/ATG may be a feasible first-line treatment even in older patients with SAA.
INTRODUCTION
Aplastic anemia (AA) is a clinical syndrome characterized by immune-mediated destruction of bone marrow (BM) hematopoietic stem cells following peripheral blood pancytopenia, which may occasionally result in fatal outcomes without appropriate treatments. 1 For younger (⩽40 years) patients with severe AA (SAA), if they have a suitable donors, allogeneic stem cell transplantation (SCT) from HLA-matched sibling donor (MSD-SCT) is the most preferred first-line treatment, [2] [3] [4] whereas its applications to older patients (440 years) is limited because of inferior outcomes or no advantage compared with the alternative treatment option of immunosuppressive therapy with antithymocyte globulin (ATG) and cyclosporin A. [5] [6] [7] [8] [9] Until recently, cyclophosphamide (Cy; 200 mg/kg) ± ATG had been the most widely used conditioning regimen for patients with SAA who received MSD-SCT. 10 However, it was associated, especially for older patients, with a considerable incidence of fatal complications. 6, [11] [12] [13] [14] [15] To overcome this challenge, a non-myeloablative conditioning regimen of fludarabine (Flu), lower-dose Cy (o 200 mg/kg) and ATG (Flu/lower-dose Cy/ATG), which might be expected to have less regimen-related toxicity and more potent immunosuppressive activities, has been recently explored with encouraging outcomes including low incidence of transplant-related mortality (TRM). [16] [17] [18] [19] [20] The reduced incidence of TRM observed in patients with SAA who received MSD-SCT using the Flu/lower-dose Cy/ATG conditioning regimen suggests that the inferior outcomes of older patients can be resolved. In addition, the upper cutoff of age for determining the most appropriate first-line treatment for patients with SAA should be reconsidered if this possibility can be validated. Therefore, whether different outcomes according to age groups in this setting are observed should be investigated. To address this issue, we analyzed the long-term outcomes of adult patients with SAA who received MSD-SCT using Flu/ lower-dose Cy/ATG conditioning regimen at our institution and compared them according to age groups.
PBSC graft was occasionally used for previously heavily-transfused patients. 21 For GVHD prophylaxis, cyclosporin A (5 mg/kg IV at day − 1, then 3 mg/kg IV from day 0) with dose adjustments targeting a trough level of 200-250 ng/mL plus short-course methotrexate (10 mg/m 2 IV at days 1, 3, 6 and 11) were administered. When patients could tolerate oral intake of medication, cyclosporin A was switched to the equivalent-dose oral form targeting a trough level of 150-200 ng/mL. Subsequently, it was gradually tapered and discontinued within 12 months if they did not experience GVHD. All patients received informed consent before receiving MSD-SCT. This retrospective study was approved by the Institutional Review Board of Seoul St Mary's Hospital of the Catholic University of Korea (Seoul, South Korea).
Supportive care
All patients received prophylactic ciprofloxacin antibiotic (1000 mg by mouth), anti-fungal agent itraconazole solution (400 mg by mouth), which was replaced with micafungin (50 mg IV) if they could no longer tolerate the oral route of drug administration, and anti-viral agent acyclovir (800 mg by mouth). In addition, they received G-CSF (5 μg/kg IV) from day 7 after transplantation. All prophylactic agents and G-CSF were discontinued when the ANC recovered to 3 × 10 9 /L. According to the risk-adaptive strategy of our institution for pre-emptive therapy, ganciclovir (10 mg/kg IV) or foscarnet (180 mg/kg IV) was administered to patients who experienced CMV reactivation. 22 
Definitions
In our study, SAA was defined as BM hypoplasia, defined as cellularity o25%, with at least two of the following criteria: (1) ANC o0.5 × 10 9 /L, (2) absolute reticulocyte count o 20 × 10 9 /L and (3) platelet count o20 × 10 9 /L. Very SAA (VSAA) was defined as ANC o0.2 × 10 9 /L in addition to meeting the diagnostic criteria of SAA. 23 The screening of paroxysmal nocturnal hemoglobinuria clones was carried out by flow cytometric analysis of CD55 and CD59 expression in erythrocytes, and glycosyl-phosphatidylinositol expression in neutrophils with cutoff values of 3.0% and 0.1%, respectively. 24, 25 Pretransplant comorbidities of patients were assessed and categorized according to hematopoietic cell transplantation-specific comorbidity index. 26 Neutrophil and platelet engraftment was defined as an ANC ⩾ 0.5 × 10 9 /L on the first 3 consecutive days and a platelet count ⩾ 20 × 10 9 /L without transfusion support on the first 7 consecutive days, respectively. Patients who failed to achieve neutrophil engraftment after day 28 were considered as having primary graft failure (GF). Secondary GF was defined as BM hypoplasia with ANC o0.5 × 10 9 /L or platelet count o20 × 10 9 /L without recovery after the initial engraftment. Transplant-related complications including GVHD, sinusoidal obstruction syndrome, hemorrhagic cystitis and other infectious complications were diagnosed and graded according to the previously published criteria. 15, [27] [28] [29] [30] [31] The cause of death was categorized according to the scheme proposed by Copelan et al. 32 
Statistical analysis
The primary objective of this study was to compare the outcomes, including GF, TRM, failure-free survival (FFS) and overall survival (OS), between the younger age group (YAG; ⩽ 40 years) and older age group (OAG; 440 years). All time-dependent parameters were calculated from the day of the first graft infusion. Primary or secondary GF, secondary hematologic malignancies and other causes of death were regarded as failures. The events for TRM, FFS and OS were defined as deaths without GF, failures and any cause of death, respectively. Continuous variables are summarized as medians and ranges, whereas categorical variables are described by counts and relative frequencies. Comparisons of baseline and transplant-related characteristics were performed using the independent two-sample t-test for continuous variables and the χ 2 test or Fisher's exact test for categorical variables. The rates of FFS and OS were calculated using Kaplan-Meier estimates and compared using the log-rank test. The engraftment, complications after transplantation, GF and TRM are described as the cumulative incidence estimate and compared using the Grey's test. The prognostic significance of covariates was determined using the Cox proportional hazards model for FFS and OS and the proportional hazards model for the subdistribution of a competing risk for GF and TRM. Because the age group was the main interest of our study, it was included in all steps of model building. Factors were considered significant if they had an associated Po 0.05 as determined by the likelihood ratio test, using two-tailed significance testing. Data were analyzed in May 2015 using R version 3.2.0 (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS

Baseline and transplant-related characteristics
The median age of all patients in our cohort was 39 (range, 15-63) years, with 54 patients (45.4%) being 440 years of age. The etiology of AA was idiopathic in 102 (87.2%), pregnancyassociated in 7 (6.0%), drug-induced in 6 (5.1%) and other in 2 (1.7%) patients. No patient had a personal or family history or extrahematopoietic clinical features suggesting constitutional AA. Before transplantation, they received transfusions of a median 16 U (range, 0-480 U) of packed red cells and 17 U (range, 0-254 U) of platelet concentrates or apheresis platelets. At a median of 12.5 (range, 0.9-345.8) months from diagnosis, they received MSD-SCT with a median 3.12 × 10 6 /kg CD34+ (range, 0.25 × 10 6 -11.76 × 10 6 /kg) and 42.60 × 10 6 /kg CD3+ cells (1.34-600.89 × 10 6 /kg). Female donor/male recipient transplant pairs were significantly more frequent in the YAG (22.2% vs 7.4%; P = 0.04), whereas the age of donors was significantly higher in the OAG (46 vs 31 years; P o 0.01). However, there were no significant differences in other baseline and transplant-related characteristics, including the proportion of patients with VSAA, history of heavily transfusion (440 U), high hematopoietic cell transplantation-specific comorbidity index (⩾3) and longer interval from diagnosis to transplantation (46 months), between the two age groups ( Table 1 ). The median follow-up duration of survivors was 4.7 (range, 0.5-11.1) years.
Engraftment and GF All patients achieved neutrophil engraftment at a median of 12 (range, 5-21) days after transplantation, except one (0.9%) who died of cerebral hemorrhage on day 10. PCR DNA fingerprinting of the short tandem repeats from peripheral blood or BM mononuclear cells in 111 (94.9%) patients revealed a median donor chimerism of 98.8% (range, 68.9-100), including a donor chimerism of ⩾ 90.0% in 105 (94.6%), at 1 month after transplantation. Platelet engraftment was observed in 110 (94.0%) patients at a median of 18 (range, 1-74) days. When we compared the median duration to neutrophil and platelet engraftment between the YAG and OAG, the neutrophil engraftment (12 vs 13 days; P = 0.04) was significantly faster in the YAG (Figure 1a ), whereas platelet engraftment (17 vs 19 days; P = 0.21) was not ( Figure 1b) .
Although primary GF was not observed, 15 (12.7%) patients experienced secondary GF at a median of 14.1 (range, 0.9-56.4) months. The cumulative incidence of secondary GF at 5 years was 14.8% (95% confidence interval (CI), 8.5-22.7%), with no significant difference between the YAG and OAG (20.8% vs 7.9%; P = 0.11) (Figure 1c) . In univariate analysis, disease severity (SAA vs VSAA) was the only potential predictor (20.4% vs 5.0% at 5 years; P = 0.06) affecting the incidence of secondary GF. However, neither age group (hazard ratio (HR) 2.12, 95% CI, 0.65-6.94; P = 0.22) nor disease severity (HR 3.29, 95% CI, 0.68-15.95; P = 0.14) was a significant factor in the multivariate analysis. Median donor chimerism of patients who experienced secondary GF significantly decreased to 91.0% (range, 0-98.0), including two (13.3%) donor chimerism of o 5.0%, from 97.6% (range, 84.7-100) at 1 month after transplantation (P = 0.01). In addition, a subgroup analysis for two age groups revealed that a lower trend of median CD34+ cell count in patients who experienced secondary GF, compared with those who did not, was observed in the OAG (1.68 × 10 6 vs 2.76 × 10 6 /kg; P = 0.06), whereas not in the YAG (3.62 × 10 6 vs 3.21 × 10 6 /kg; P = 0.68). All patients who experienced secondary GF remained alive, including 10 (66.7%; nine in the YAG and one in the OAG) who received second allogeneic SCT with sustained engraftment and 5 (33.3%; two in the YAG and three in the OAG) who received conservative care with transfusion dependency.
GVHD and other complications At a median of 39 (range, 21-141) days, 14 patients (11.2%; six in the YAG and eight in the OAG) experienced acute grade II-IV GVHD. Of these, 13 patients (11.1%) had acute grade II and 1 (0.9%) had acute grade III GVHD. Chronic GVHDs were observed in 10 patients (8.5%; five in both the YAG and OAG) at a median of 6.7 (range, 2.7-20.8) months, including both one (0.9%) moderate and severe chronic GVHD. The cumulative incidence of acute grade II-IV and chronic GVHD (at day 100 and 5 years, respectively) was 9.4% (95% CI, 5.0-15.5) and 8.8% (95% CI, 4.5-14.9), respectively, with no significant difference between the YAG and OAG (9.5% vs 9.3%; P = 0.42 and 8.1% vs 9.5%; P = 0.80, respectively; Figures 2a and b) . In univariate analysis, hematopoietic cell transplantation-specific comorbidity index (o 3 vs ⩾ 3) was the only potential predictor (13.0% vs 2.2% at 5 years; P = 0.05) affecting the incidence of chronic GVHD, whereas there was no predictor that affected the incidence of acute grade II-IV GVHD (P40.10). However, neither age group (hazard ratio (HR) 0.81, 95% CI, 0.24-2.72; P = 0.73) nor hematopoietic cell transplantation-specific comorbidity index (HR 0.81, 95% CI, 0.24-47.39; P = 0.09) was a significant factor of the incidence of chronic GVHD in the multivariate analysis.
At a median of 41 (range, 21-66) days, 60 patients (51.3%; 28 in the YAG and 32 in the OAG) received pre-emptive treatment for CMV reactivation. CMV disease developed in seven patients (6.0%; three in the YAG and four in the OAG), including pneumonia in two (1.7%), retinitis in two (1.7%) and gastroenteritis in three (2.6%). Herpes zoster and hemorrhagic cystitis grade II-IV were observed in 29 patients (24.8%; 15 in the YAG and 14 in the OAG) at a median of 199 (range, 45-2223) days and 8 (6.8%; three in the YAG and five in the OAG) at a median of 39.5 (range, 7-643) days, respectively. Other grade III-IV infectious complications developed in 30 patients (25.6%; 19 in the YAG and 11 in the OAG) at a median of 35.5 (range, 5-1232) days. There were no significant differences in the cumulative incidence of these complications between the YAG and OAG (P40.05; Table 2 ). In addition, secondary AML and myelodysplastic syndrome, which might have originated from the donor cells, developed in two patients (1.7%; one each in the YAG and OAG) at 4.3 and 41.5 months after transplantation, respectively.
Transplant-related mortality At a median of 1.6 (range, 0.3-53.6) months, nine patients (7.6%; three in the YAG and six in the OAG) had died, due to acute Abbreviations: BM = bone marrow; HCT-CI = hematopoietic cell transplantation-specific comorbidity index; IST = immunosuppressive therapy; PNH = paroxysmal nocturnal hemoglobinuria; SAA = severe aplastic anemia; VSAA = very severe aplastic anemia.
Impact of age on outcomes in MSD-SCT for SAA SH Shin et al GVHD in one (in the OAG), infectious complications in five (two in the YAG and three in the OAG), secondary hematologic malignancies, including AML, and myelodysplastic syndrome in two (one each in the YAG and OAG) and cerebral hemorrhage in one (in the OAG). The cumulative incidence of TRM at 5 years was 8.1% (95% CI, 3.9-14.2), with no significant difference between the YAG and OAG (5.4% vs 11.1%; P = 0.19) (Figure 2c) . In univariate analysis, disease severity (SAA vs VSAA) was the only potential predictor (2.6% vs 18.1% at 5 years; P o 0.01) affecting the incidence of TRM. In multivariate analysis, disease severity (HR 0.15, 95% CI, 0.03-0.70; P = 0.02) was a significant factor, whereas age group (HR 0.49, 95% CI, 0.13-1.86; P = 0.29) was not.
FFS and OS
The estimated FFS and OS rates at 5 years were 77.2% (95% CI, 67.5-84.3%) and 91.5% (95% CI, 84.0-95.6%), respectively. They were not significantly different (73.7% vs 81.0% at 5 years; P = 0.73 and 93.7% vs 88.9% at 5 years; P = 0.20, respectively) between the YAG and OAG (Figures 3a and b) . In addition, when we classified patients into four age groups, 33 patients (28.2%) were ⩽ 30, 30 (25.6%) were 31-40, 41 (35.0%) were 41-50 and 13 (11.1%) were 450 years of age. There was no significant difference in FFS (75.8%, 70.3%, 77.5 and 92.3%, respectively, at 5 years; P = 0.61) or OS rates (97.0%, 91.0%, 87.7% and 92.3%, respectively, at 5 years; P = 0.53) (Figures 3c and d) . In univariate analysis, disease severity (SAA vs VSAA) was the only potential predictor (97.4% vs 81.1% at 5 years; P o 0.01) affecting the OS rate, whereas there was no predictor that affected the FFS rate (P40.10). In multivariate analysis, disease severity (HR 0.15, 95% CI, 0.03-0.74; P = 0.02) was the only significant factor affecting OS rate, whereas age group (HR 0.50, 95% CI, 0.13-2.03; P = 0.34) was not.
DISCUSSION
Until recently, younger patients with SAA, if a suitable donor was available, received MSD-SCT as a first-line treatment. [2] [3] [4] However, it has been under debate whether MSD-SCT was an acceptable option for older patients before experiencing immunosuppressive therapy failure because of unacceptable outcomes owing to the high incidence of TRM, which was reported by several studies for MSD-SCT mainly using a conditioning regimen of Cy (200 mg/kg) ± ATG. 6, 7 The Center for International Blood and Marrow Transplant Research registry-based retrospective study revealed a significantly lower OS rate of patients 440 years old compared with those 20-40 and o20 years old (53%, 72% and 82%, respectively, at 5 years; P o 0.01) owing to the higher incidences of acute grade II-IV (27%, 17% and 11%, respectively; P o0.01) and chronic GVHD (27%, 25% and 11%, respectively; P o0.01). 6 The European Group for Blood and Marrow Transplantation registry-based retrospective study also reported significantly lower OS rates of patients 440 years old compared with those with 17-40 and ⩽ 16 years old (27%, 53% and 60%, respectively; P o0.01). 7 Another recent large registry-based retrospective study by the SAA Working Party of the European Group for Blood and Marrow Transplantation revealed that age of ⩾ 20 years remained a significant factor, which affected the OS rate (HR 1.56; 95% CI, 1.11-2.19; P = 0.01). 8 In addition, a retrospective study by the Seattle group reported that OS rate of patients 440 years old was modestly unsatisfactory (65% at 10 years). 9 In several other studies, although they analyzed the outcomes of relatively younger patients, a considerable incidence of acute grade II-IV (11-33%) and chronic GVHD (21-56%) with a relatively high overall mortality rate (12-41%) was observed, with age as a significant factor that affected the GVHD incidence or OS rate. [11] [12] [13] [14] [15] Consequently, these results suggest that a conditioning regimen that can reduce the high incidence of TRM should be investigated to improve outcomes of older patients, considering that they are more vulnerable to regimen-related toxicity.
The optimal conditioning regimens of allogeneic SCT for patients with SAA need sufficient immunosuppression to prevent graft rejection, whereas intensive myelosuppression to create room for engraftment may be relatively unnecessary because its pathogenesis is characterized by autoreactive T-cell-mediated destruction of hematopoietic stem cells. 4 Considering the potent immunosuppressive activity with low systemic toxicity of Flu as a purine analog, it can be an attractive additive for patients to achieve sustained engraftment without increased regimenrelated toxicity. 33 In addition, lower-dose Cy ( o200 mg/kg) may be beneficial to reduce the incidence of early and late complications, including hepatotoxicity, cardiotoxicity and hemorrhagic cystitis, which were frequently observed when higher dose was used. [34] [35] [36] Based on these findings, MSD-SCT using a non-myeloablative conditioning regimen of Flu/lowerdose Cy/ATG was attempted by several investigators. [16] [17] [18] [19] [20] An early retrospective study by Resnick et al., 16 although a very small number of patients was analyzed, reported a low incidence of acute grade II-IV and chronic GVHD (8.3% and 12.5%, respectively), which resulted in an acceptable OS rate (84.0% at 5 years). Subsequently, several studies compared the outcomes of patients who received MSD-SCT using Flu/lower-dose Cy ± ATG and Cy ± ATG conditioning regimen. 17, 18 George et al., 17 in a retrospective study, reported that patients who received the Flu/lower-dose Cy ± ATG achieved significantly faster neutrophil engraftment (12 vs 16 days; P o0.01) and a lower incidence of GF (2.9% vs 30.7%; P o0.01), which resulted in a higher OS rate (82.8% vs 46.1%; P o 0.01) compared with those who received the Cy ± ATG. In addition, a phase III prospective study by Kim et al. 18 reported a significantly lower incidence of regimen-related toxicity of the Flu/lower-dose Cy/ATG group compared with that of the Cy+ATG group (23.3% vs 55.0%; P o0.01).
Consequently, these previous studies suggested that an acceptable OS rate could be achieved in older patients with SAA, followed by a reduced incidence of regimen-related toxicity if they received MSD-SCT using Flu/lower-dose Cy/ATG conditioning regimen. This is supported by a recent retrospective study by Maury et al. 23 who reported a significantly higher age-adjusted OS rate of patients who received Flu/lower-dose Cy ± ATG conditioning regimen compared with those who received Cy ± ATG (P = 0.04), with no significant difference in OS rate between patients 30-39 and ⩾ 40 years old in the Flu/lower-dose Cy ± ATG group (P = 0.30). However, a small number of analyzed patients and the heterogeneity of the transplant-related strategy including GVHD prophylaxis in this study suggest that the feasibility of MSD-SCT using Flu/lower-dose Cy/ATG for older patients should be validated by further investigations.
In our current retrospective study, 117 consecutive adult patients with SAA who received MSD-SCT using Flu/lower-dose Cy/ATG conditioning regimen achieved encouraging long-term FFS and OS rates (77.2% and 91.5%, respectively, at 5 years) following a low incidence of acute grade II-IV and chronic GVHD, GF and TRM (9.4%, 8.8% and 14.8%, and 8.1%, respectively, at 5 years). Notably, the incidence or rate of all outcomes, except for significantly faster neutrophil engraftment (12 vs 13 days; P = 0.04) in the YAG, were not significantly different between the YAG and OAG (P40.10). Our results can be explained primarily by reduced regimen-related toxicity using the Flu/lower-dose Cy/ATG conditioning regimen. Especially, the very low incidences of acute grade II-IV and chronic GVHD is explained by the immunomodulatory effects of Flu, which is also supported by experimental studies using a murine mouse allogeneic SCT model, and an ethnic factor of a relatively homogenous population in Korea. [37] [38] [39] [40] In patients of other ethnic groups, the incidences of GVHD are expected to be relatively higher, which may result in reduced benefits of Flu/lower-dose Cy/ATG conditioning regimen. However, we suggest that other advantages using our conditioning regimen remains applicable to them.
In conclusion, our study indicates that MSD-SCT using Flu/lower-Cy/ATG conditioning regimen may be a feasible option as a first-line treatment for older patients with SAA, considering that the outcomes were not inferior compared with those in younger patients. Especially that there were no significant differences in FFS and OS rates when we classified patients into four age groups suggests that patients 450 years old may be considerable candidates if they have adequate organ function and performance status. These results support that the upper cutoff of age for determining the most appropriate first-line treatment for patients with SAA may be changed in conjunction with further studies that compare the outcomes between MSD-SCT using Flu/lower-CY/ATG and immunosuppressive therapy. In addition, the value of this study may be emphasized considering that the patients in our cohort received a consistent transplant-related strategy of a conditioning regimen, GVHD prophylaxis and supportive care in a study analyzed by the outcomes of the largest, until now, number of patients with SAA who received MSD-SCT using Flu/lower-dose Cy/ATG. However, further investigations are required to establish whether the high incidence of secondary GF observed in this study, particularly in the YAG, resulted from the low intensity of our conditioning regimen, although previous studies reported that the Flu/lower-dose Cy/ATG resulted in a lower incidence of GF compared with the Cy/ATG. 17, 18 In addition, confirmatory validations by well-designed prospective studies are required, considering several limitations of our study including inherited selection bias resulting from retrospective nature.
